Global Central Nervous System Partnering 2012-2018: Deal trends, players and financials

Thursday, February 8, 2018 Research News
Email Print This Page Comment bookmark
Font : A-A+

Global Central Nervous System Partnering 2012 to 2018 provides the full collection of Central Nervous System disease deals signed between the world's pharmaceutical and biotechnology companies since 2012.

LONDON, Fev. 8, 2018 /PRNewswire/ -- Download the full report: https://www.reportbuyer.com/product/3021527 Trends in Central Nervous System partnering

dealsFinancial deal terms for headline, upfront and royalty by stage of developmentCentral Nervous System partnering agreement structureCentral Nervous System partnering contract documentsTop Central Nervous System deals by valueMost active Central Nervous System dealmakersMost of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.The report takes readers through the comprehensive Central Nervous System disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Central Nervous System deals.The report presents financial deal terms values for Central Nervous System deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.The initial chapters of this report provide an orientation of Central Nervous System dealmaking trends.Chapter 1 provides an introduction to the report.Chapter 2 provides an overview of the trends in Central Nervous System dealmaking since 2012 covering trends by year, deal type, stage of development, technology type and therapeutic indication.Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.Chapter 4 provides a review of the leading Central Nervous System deals since 2012. Deals are listed by headline value. The chapter includes the top 25 most active Central Nervous System dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.Chapter 5 provides comprehensive access to Central Nervous System deals since 2012 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.Chapter 6 provides a comprehensive directory of all Central Nervous System partnering deals by specific Central Nervous System target announced since 2012. The chapter is organized by specific Central Nervous System therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.In addition, a comprehensive appendix is provided with each report of all Central Nervous System partnering deals signed and announced since 2012. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.The report also includes numerous tables and figures that illustrate the trends and activities in Central Nervous System partnering and dealmaking since 2012.In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Central Nervous System technologies and products.Report scopeGlobal Central Nervous System Partnering 2012 to 2018 is intended to provide the reader with an in-depth understanding and access to Central Nervous System trends and structure of deals entered into by leading companies worldwide.Global Central Nervous System Partnering 2012 to 2018 includes:Trends in Central Nervous System dealmaking in the biopharma industry since 2012Analysis of Central Nervous System deal structureAccess to headline, upfront, milestone and royalty dataAccess to hundreds of Central Nervous System deal contract documentsComprehensive access to over 3500 Central Nervous System deal recordsThe leading Central Nervous System deals by value since 2012Most active Central Nervous System dealmakers since 2012The report includes deals for the following indications: Cerebral palsy, Creutzfeldt Jakob disease, Dizziness, Epilepsy, Faints, Falls, Guillain Barre syndrome, Headache, Meningitis (Bacterial, Meningococcal, Pneumococcal), Mycobacterium tuberculosis (TB), Haemophilus influenzae Type B (Hib), Migraine, Motor Neurone Disease (Amyotrophic Lateral Sclerosis/Lou Gehrig's Disease, Multiple sclerosis, Nausea, Neuropathy, Pain, Neuralgia, Fibromyalgia, Paralysis, Parkinson's disease, Restless leg syndrome, Spinal cord, Stroke, Stuttering, Traumatic Brain Injury, Vertigo, Weakness, plus other CNS indications.In Global Central Nervous System Partnering 2012 to 2018, available deals and contracts are listed by:Headline valueUpfront payment valueRoyalty rate valueStage of development at signingDeal component typeTechnology typeSpecific therapy indicationEach deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.The Global Central Nervous System Partnering 2012-2018 report provides comprehensive access to available deals and contract documents for over 1,500 central nervous system deals. Analyzing actual contract agreements allows assessment of the following:• What are the precise rights granted or optioned?• What is actually granted by the agreement to the partner company?• What exclusivity is granted?• What is the payment structure for the deal?• How are the sales and payments audited?• What is the deal term?• How are the key terms of the agreement defined?• How are IPRs handled and owned?• Who is responsible for commercialization?• Who is responsible for development, supply, and manufacture?• How is confidentiality and publication managed?• How are disputes to be resolved?• Under what conditions can the deal be terminated?• What happens when there is a change of ownership?• What sublicensing and subcontracting provisions have been agreed?• Which boilerplate clauses does the company insist upon?• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?• Which jurisdiction does the company insist upon for agreement law?Download the full report: https://www.reportbuyer.com/product/3021527 About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: sarah@reportbuyer.com  Tel: +1 (718) 213 4904 Website: www.reportbuyer.com  

Cision View original content:http://www.prnewswire.com/news-releases/global-central-nervous-system-partnering-2012-2018-deal-trends-players-and-financials-300595845.html

SOURCE ReportBuyer



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store